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Cognitive deficits are common in Parkinson’s disease. Previous cross-sectional research
has demonstrated a link between cognitive impairments and fronto-striatal dopaminergic
dysmodulation. However, longitudinal studies that link disease progression with altered
task-evoked brain activity are lacking. Therefore, our objective was to longitudinally
evaluate working-memory related brain activity changes in Parkinson’s disease patients
with and without mild cognitive impairment (MCI). Patients were recruited within
a longitudinal cohort study of incident patients with idiopathic parkinsonism. We
longitudinally (at baseline examination and at 12-months follow-up) compared 28 patients
with Parkinson’s disease without MCI with 11 patients with Parkinson’s disease and
MCI. Functional MRI blood oxygen level dependent signal was measured during a
verbal two-back working-memory task. Patients with MCI under-recruited bilateral medial
prefrontal cortex at both time-points (main effect of group: p < 0.001, uncorrected).
Critically, a significant group-by-time interaction effect (p < 0.001, uncorrected) was found
in the right fusiform gyrus, indicating that working-memory related activity decreased for
patients with Parkinson’s disease and MCI between baseline and follow-up, while patients
without MCI were stable across time-points. The functional connectivity between right
fusiform gyrus and bilateral caudate nucleus was stronger for patients without MCI relative
to patients with MCI. Our findings support the view that deficits in working-memory
updating are related to persistent fronto-striatal under-recruitments in patients with early
phase Parkinson’s disease and MCI. The longitudinal evolution of MCI in Parkinson’s
disease translates into additional task-evoked posterior cortical changes.
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INTRODUCTION
Cognitive impairment frequently accompanies the characteristic
motor deficits in Parkinson’s disease (PD), ranging from mild
cognitive impairment (MCI) to dementia (Kehagia et al., 2010;
Svenningsson et al., 2012). Approximately 20–40% of patients
with PD have MCI at an early phase (Aarsland et al., 2010), and
the risk of developing PD dementia (PDD) is markedly increased
for patients with MCI compared to patients without MCI (Janvin
et al., 2006; Broeders et al., 2013; Pedersen et al., 2013).
Previous cross-sectional research has linked cognitive impair-
ments in PD to both structural and functional brain deficits
(Kehagia et al., 2010; Svenningsson et al., 2012), and early-phase
alterations are commonly related to working-memory and exec-
utive processes (Owen, 2004; Monchi et al., 2007; Marklund
et al., 2009). In a previous cross-sectional study, we showed
that patients with PD and MCI under-recruited bilateral ante-
rior cingulate cortex (ACC) and right caudate nucleus compared
with patients without MCI during working-memory updating
(Ekman et al., 2012). Additionally, a recent publication reported
findings in accordance with our study (Nagano-Saito et al.,
2014). Fronto-striatal hypo-activity has also been demonstrated
for patients with PD and impaired executive functions rela-
tive to non-impaired patients (Lewis et al., 2003), and impaired
working-memory is associated with nigro-striatal (Rinne et al.,
2000; Cools, 2006; Ekman et al., 2012), andmeso-cortical (Mattay
et al., 2002; Monchi et al., 2007) dopaminergic dysfunction.
Cross-sectional studies have thus provided information on the
anatomical and neurochemical bases of cognitive deficits in PD.
However, longitudinal cohort studies are fundamental in order to
better understand underlying mechanisms (Kehagia et al., 2010;
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Monchi and Stoessl, 2012). Research using longitudinal method-
ology is generally more sensitive in detecting brain changes, and
not as susceptible to cohort differences as cross-sectional method-
ology (Raz, 2005; Nyberg et al., 2010). However, only a limited
number of longitudinal studies have linked brain changes to cog-
nitive decline in PD. Functional changes have been related to
evolving glucose metabolism decline within cognitive networks
of prefrontal- and parietal cortices in patients with PD (Huang
et al., 2007), and tests probing posterior cortical function rather
than tests probing fronto-striatal cortical function have been
demonstrated to enhance predictions of global cognitive decline
(Williams-Gray et al., 2007, 2013). Critically, no longitudinal
study has previously evaluated task-evoked brain responses in
relation to cognitive impairments in PD. Task-evoked methodol-
ogy offers a unique possibility to evaluate physiological responses
within the operative brain in relation to cognitive deficits. Thus,
the aim of this study was to longitudinally (at time for initial
PD-diagnoses and at 12-months follow-up) assess changes in
working-memory related brain responses using functional MRI
in a population-based cohort of patients with PD, with and with-
out MCI. Because patients with PD and MCI have increased risk
for PDD (Janvin et al., 2006; Broeders et al., 2013), we expect that
a large proportion of the patients with MCI eventually progress
to PDD. However, although a large proportion of patients with
MCI convert to dementia, some patients never progress or even
revert to normal cognition, which implies heterogeneous causes
(Richard and Brayne, 2014). To ensure that the patients with PD
andMCI did not convert to normal cognition or PDD across time
(i.e., to increase the prognostic accuracy of MCI in respect to
prodromal PDD), repeated neuropsychological testing was car-
ried out (Pedersen et al., 2013). Global cognitive decline might
be related to neural dysfunction with posterior cortical basis
rather than fronto-striatal circuits (Huang et al., 2007; Williams-
Gray et al., 2007). Therefore, we hypothesized that posterior
cortical changes across time might be more pronounced than
fronto-striatal changes in patients with PD and MCI, reflecting
progression toward prodromal PDD.
MATERIALS AND METHODS
PARTICIPANTS
The recruitment process was conducted within the “newly diag-
nosed parkinsonism in Umeå” (NYPUM) project, which is a
longitudinal population-based cohort study of incident patients
with idiopathic parkinsonism, including PD. All physicians in the
Umeå catchment area (about 142 000 inhabitants) were continu-
ally requested for referral of all patients with suspected parkinson-
ism to the Department of Neurology at Umeå University, during
the inclusion interval January 1, 2004, to April 30, 2009. Patients
were included if they fulfilled the UK Parkinson’s Disease Society
Brain Bank clinical diagnostic criteria for definite PD (UKPDS;
Gibb and Lees, 1988) at the latest available re-evaluation (36–60
months after initial diagnosis). The participants performed the
first (baseline) neuropsychological examination and fMRI scan-
ning approximately 1–2 months after initial PD-diagnosis, and
all participants were drug-naïve regarding dopaminergic med-
ication at that time-point (see Table 1 for demographic data).
However, at the time for the first follow-up (Mean = 12 months
and 23 days, SD = 2 months and 15 days) all participants (except
Table 1 | Demographics and clinical characteristics.
PDMCI+ (n = 11) PDMCI− (n = 28) Difference Difference at Main effect Group-by-time
at baseline 12-months follow-up of group interaction
Male/female (bimanual
p-value)
9/2 (p = 0.07) 13/15 (p = 0.85) n.a. n.a. n.a. n.a.
Years of education 9.55 (3.9) 12.5 (5.4) 0.10 n.a. n.a. n.a.
Age at baseline
examination
65.9 (9.0) 67.5 (10.2) 0.66 n.a. n.a. n.a.
Years between symptom
onset and PD-diagnosis
2.22 (2.2) 2.0 (1.5) 0.76 n.a. n.a. n.a.
Time-points Baseline 12-months Baseline 12-months
Mine-mental state
examination
28.8 (1.3) 28.7 (1.6) 29.4 (0.8) 29.4 (0.9) 0.12 0.11 0.47 0.77
UPDRS-III motor scores 31.5 (12.0) 23.2 (12.2) 22.9 (9.2) 20.3 (9.2) 0.01 0.21 0.91 0.47
LED 0 422.7 (84.0) 0 296.4 (159.7) n.a. 0.01 n.a. n.a.
MADRS 4.3 (3.7) 2.9 (2.1) 4.4 (3.4) 3.6 (3.7) 0.41 0.26 0.71 0.69
Executive functions 41.9 (5.9) 42.2 (15.1) 54.1 (10.5) 59.7 (14.1) <0.01 <0.01 <0.01 0.13
Episodic memory 37.5 (8.4) 37.7 (7.2) 514 (5.3) 52.2 (8.3) <0.01 <0.01 <0.01 0.95
Attention/working memory 33.9 (8.1) 36.2 (7.0) 47.4 (5.5) 47.3 (5, 1) <0.01 <0.01 <0.01 0.21
Language 51.6 (12.5) No values 52.3 (13.4) No values 0.44 n.a. n.a. n.a.
Visuospatial functions 50.1 (9.2) 52.2 (4.6) 57.4 (3.4) 56.6 (5.2) <0.01 0.02 <0.01 0.14
The data are mean values with standard deviations in parentheses. The five cognitive domains for assessing MCI (executive functions, episodic memory,
attention/working-memory, language and visuospatial functions) represent means of the included domain-specific tests age-matched t-values. n, numbers of partici-
pants. UPDRS-III (unified Parkinson’s disease rating scale, part 3) and LED (levodopa equivalent doses). MADRS (Montgomery and Åsberg Depression Rating scale).
n.a., not applicable. Analyses of group differences at baseline, 12-months, main effect of group, and group-by-time interaction are reported as p-values.
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one cognitively healthy participant) received dopaminergic anti-
parkinsonian medication on a daily basis. Dopamine treatment
were recorded and calculated as levodopa equivalent dose (LED)
according to the conversion factors used by Tomlinson et al.
(2010). This study was approved by the ethics committee of the
Faculty of Medicine at Umeå University, Umeå, Sweden.
CLASSIFICATION OF MCI AND FINAL GROUPS
We classified MCI by assessing The Movement Disorders Society
commissioned taskforce criteria for MCI in PD (Litvan et al.,
2012) in the same fashion as previously described (Ekman et al.,
2012). In brief, the included neuropsychological tests tapped five
different cognitive domains: executive functions [Wisconsin Card
Sorting Test (WCST) (total errors and perseverative responses)
and animal fluency], attention/working-memory (digit span
backwards and trail making test, part B), episodic memory
[Brief Visuospatial Memory Test revised, (average scores of free
and delayed recall); Free and Cued Selective Reminding Test,
free recall], visuospatial function (Judgment of Line Orientation
Test), and language [Boston Naming Test (BNT)]. Patients who
scored ≥1.5 SDs below the normative age-matched mean value
in at least two cognitive test measures were classified with MCI.
Because only one cognitive measure was assessed in the lan-
guage and visuospatial domains, MCI was classified on level I
criteria (i.e., subtyping not possible). Because we had available
neuropsychological data at 36-monts follow-up, we controlled
that results at 36-months follow-up confirmed the MCI classi-
fications set at 12-months to increase accuracy. In conformity
with a recent large-scale pooled study (Aarsland et al., 2010),
no subjective measures were part of the MCI classification.
However, all but one participant classified with MCI reported
complaints of subjective cognitive decline. The exclusion process
is described in Figure 1. Dementia was assessed using consen-
sus criteria (Emre et al., 2007), reflecting both subjective (deficits
severe enough to significantly impair daily life independent of
impairment due to non-cognitive symptoms of PD assessed with
a clinical interview and the Parkinson’s disease questionnaire 39)
and objective measures (cognitive impairment in at least two
cognitive domains with performance ≥2 SDs below normative
age-matched t-values; one patient was excluded with suspected
dementia of Lewy-Body type). The cut-off for major depression
was set to a score of >17 (according to the Montgomery and
Åsberg Depression Rating scale; Montgomery and Åsberg, 1979),
but no participants were excluded due to depression. Patients
classified with MCI at baseline but not at 12-, or 36-months
follow-up were excluded due to unclear cognitive status. After the
initial exclusions, the sample consisted of 39 participants whom
all conducted the neuropsychological- and fMRI examinations
at both time-points with satisfactory data collection (one par-
ticipant lacked neuropsychological data at 12-months, but was
confirmed as MCI at 36-months). The final groups consisted of
11 participants that had PD with MCI (PDMCI+) at both time-
points, and 28 participants who had PD without MCI (PDMCI−)
at both time-points. Out of the 11 PDMCI+ participants, seven
were treated with levodopa at 12-months follow-up, three with
a combination of levodopa and dopamine agonists, and the last
FIGURE 1 | Flow-chart of study profile. Of 67 enrolled Parkinson’s disease patients, 51 had conducted neuropsychological assessments and fMRI at both
time-points with either a manifested MCI or were cognitive stable. SD, standard deviation.
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patient with dopamine agonists singly. The equivalent number for
PDMCI− were: 12 were treated with dopamine agonists, 10 with
levodopa, five with a combination of levodopa and dopamine
agonists, and the last patient did not receive any dopaminergic
medication at 12-months follow-up.
EXPERIMENTAL PROCEDURES AND fMRI DATA ACQUISITION
The procedures for the fMRI data acquisition have been described
previously (Ekman et al., 2012). In brief, during scanning par-
ticipants performed a verbal working-memory 2-back updating
task. The task demanded the participants to actively maintain
and update information (nouns) that regularly were presented
on the screen. The participants were instructed to respond “yes”
(right index finger) when the presented noun matched the one
two items earlier and “no” (left index finger) when it differed,
by pushing MRI-compatible keypads. During the baseline con-
dition participants were instructed to do nothing except keeping
their gaze fixed on a small circle that were displayed at the cen-
ter of the screen. The fMRI acquisition was conducted using
two different scanners: a 1.5T Philips Intera scanner and a 3T
Philips Achieva scanner (both scanners from Philips, Eindhoven,
Netherlands). The sequences had the following parameters for
the 1.5T scanner: repetition time (TR): 3000ms, echo time (TE)
50ms, flip angle 90◦, field of view: 22 × 22 cm, 64 × 64 matrix
and 4.40mm slice thickness (voxel size 3.44 × 3.44 × 4.40mm).
During every repetition time, 33 slices were acquired. To avoid
effects of signal saturations, five dummy scans were performed
prior to the image acquisition. Acquisition parameters for the 3T
scanner were: TR 1500ms, TE 30ms, flip angle 70◦, field of view
22 × 22, 64 × 64 matrix and 4.65mm slice thickness (voxel size
3.44 × 3.44 × 4.65). During every repetition time, 31 slices were
acquired. Ten dummy scans were performed prior to the image
acquisition. For PDMCI− the scanner distributions were: 19 par-
ticipants performed the workingmemory task in the 1.5T scanner
and 9 participants in the 3T scanner. The equivalent number for
PDMCI+ were 6 in the 1.5T scanner and 5 in the 3T scanner.
All included participants conducted the experiment on the same
scanner at both time-points.
STATISTICAL ANALYSES
Preprocessing and statistical analyses of fMRI-data were done
with Statistical Parametric Mapping version 8 (SPM 8, Welcome
Department of Imaging Neuroscience, London, UK) run in
Matlab (MathWorks). The preprocessing included slice-timing
correction within each volume to adjust for differences in slice
acquisition, Movement correction were performed by realign
and unwarp to the first image in the series. To consider group-
specific anatomical brain differences, all participants were ini-
tially normalized to the Montreal Neurological Institute (MNI)
echoplanar-imaging template. In a second step, normalization
was done to group-specific means for patients with and without
MCI at each time point. The mean-normalized brain templates
were then projected to the total mean of all participants. Finally,
the images were smoothed by using an 8mm FWHM isotropic
Gaussian filter kernel. For functional MRI data, effects were mod-
eled in the framework of the general linear model (GLM; Friston
et al., 1995). The event-related fMRI responses were modeled as
regressors containing delta functions that represented onsets of
word stimuli, and the regressors were convolved with a canonical
haemodynamic response function. Model estimations from each
participant were input into a second-level factorial analysis with
the factors group, time-point, subject, and scanner. Motor scores
(UPDRS-III) and levodopa equivalent doses (LED; daily levodopa
and dopamine agonist dosages combined) for each participant
were input as covariate in the model due to significant group
differences (Table 1). Due to the low number of patients treated
with dopamine agonists in PDMCI+, no sub-analyses of potential
medication effects on cognition were conducted. The statistical
threshold was set to P < 0.001, uncorrected, and the cut-off for
number of contiguous voxels (k) was ≥10 in the whole-brain
fMRI analyses. Results significant at p < 0.005 (≥ 10 contiguous
voxels) are reported as a trend.
To evaluate possible confounding effects from scanner dif-
ferences, we performed F-tests (P < 0.001) on main effect of
scanner, group-by-scanner, time-by-scanner, and group-by-time-
by-scanner interactions (Stonnington et al., 2008). Pooled analy-
ses have previously been conducted to handle MRI-scanners with
different magnetic field strengths (Abdulkadir et al., 2011; Ekman
et al., 2012; Marchewka et al., 2014). Furthermore, we analyzed
effect sizes (Cohen’s d) on each scanner separately in our reported
main effects to ensure equivalence across scanners. One region-
of-interest (ROI) analysis in the right caudate was conducted, and
the ROI has been previously defined (Ekman et al., 2012).
A psychophysiological interaction (PPI) analysis was per-
formed to evaluate how a ROI functionally interacted with other
brain areas during task-performances (Friston et al., 1997). In
brief, we performed a second GLM analysis that included one
regressor representing the BOLD signal time course in a given
ROI, one regressor representing the psychological variable of
interest (i.e., working memory condition>baseline condition),
and finally one regressor representing the interaction of the for-
mer two. The ROIs signal time course (contrast vectors: task
condition>baseline condition) for each individual was extracted
from a sphere (radius of 6mm) centered on the seeds peak voxel
(derived from the group-by-time interaction post-hoc analysis).
The statistical threshold in the PPI-analysis was set to p < 0.001,
and the cut-off for number of contiguous voxels was ≥10.
Longitudinal analyses of the right caudate ROI, demograph-
ics, clinical characteristics, and the scanner-task behavioral data
were assessed within the framework of the GLM using a two-
factor (group-by-time) repeated-measures ANOVA. Analyses of
group differences at a specific time-point were conducted using
independent-samples t-test. The statistical threshold in the ROI-
and the behavioral analyses was set to p < 0.05. Group compar-
isons of behavioral performances were analyzed as one-tailed due
to á priori hypotheses, and demographic data were analyzed as
two-tailed. Gender distribution was analyzed with a binominal
test.
RESULTS
BEHAVIORAL DATA
Neuropsychological testing revealed that, PDMCI+ had signifi-
cantly reduced performances (main effect of group across base-
line and 12-months) within all cognitive domains (except the
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language domain that was assessed only at baseline) compared
to PDMCI− (Table 1). There were no significant group-by-time
interaction effects or main effects of time.
As shown in Figure 2, a significant main effect of group
was also evident when comparing accuracy (percentage correct
answers) on the scanner working-memory 2-back task [F(1, 36) =
7.12, p = 0.01]. There was no main effect of group regarding
reaction times [RT; F(1, 36) = 0.31, p = 0.58]. The group-by-time
interaction effect was not significant for performance accuracy
[F(1, 36) = 0.21, p = 0.65], but approached significance for RTs
[F(1, 36) = 3.43, p = 0.07]. There was no main effect of time
(p > 0.10).
NEUROIMAGING DATA
Whole-brain analyses
When comparing working-memory related BOLD-signal inten-
sity, PDMCI+ displayed significant under-recruitment compared
to PDMCI−. This was seen as a main effect of group in bilat-
eral medial prefrontal cortex, left precentral gyrus, and as a
trend in left orbitofrontal cortex, left superior frontal gyrus,
right postcentral gyrus, and in the right inferior temporal cor-
tex (Table 2, Figure 3). No overlap was observed between our
reported main effects of group and a main effect of scanner analy-
sis, or a group-by-scanner analysis. Furthermore, quantifications
of the responses for the two scanners separately showed consistent
magnitude of BOLD-signal change on both scanners, with large
effect sizes (Cohen’s d > 0.80). Less conclusive evidence due to
potential influences of the scanner factor was observed in right
putamen, left parietal cortex, left cuneus, precuneus, and the left
occipital cortex (Supplementary Table 1).
A group-by-time interaction effect was evident in the right
fusiform gyrus (Figure 4), right vermis, and as a trend in left infe-
rior temporal cortex (Table 3). Specifically, PDMCI+ decreased
their BOLD-signal intensity in the fusiform gyrus between base-
line and 12-months, while PDMCI− were stable across both
time-points. By contrast, PDMCI+ increased their BOLD-signal
intensity between baseline and 12-months in right parietal cortex
and left prefrontal cortex while PDMCI− were again stable across
time-points. No overlap was observed between our reported
group-by-time interaction effects, and a scanner-by-time inter-
action, a group-by-scanner interaction, or a group-by-time-by-
scanner interaction effect. Less conclusive evidence due to poten-
tial influences of the scanner factor, was observed in right cere-
bellum and in left dorsolateral prefrontal cortex (Supplementary
Note 1).
We performed a PPI-analysis to evaluate if the right fusiform
gyrus had functional connectivity with additional working-
memory related brain regions. A main effect of group revealed
that PDMCI− had stronger functional connectivity relative to
Table 2 | Main effects of group in BOLD-signal intensity between
patients with Parkinson’s disease with and without MCI.
Brain region Side Peak (x, y, z) F K
PATIENTS WITHOUT MCI > PATIENTS WITH MCI
Frontal
Precentral gyrus L −42, 4, 30 19.29 23
Medial prefrontal L/R 0, 54, 28 22.12 148
Orbitofrontal cortex* L −24, 34, −12 15.92 42
Superior frontal gyrus* L −22, 16, 64 14.93 24
Parietal
Postcentral gyrus* R 44, −18, 48 14.87 48
Temporal
Inferior temporal* R 48, −18, −22 14.42 39
PATIENTS WITHOUT MCI < PATIENTS WITH MCI
Frontal
Orbitofrontal cortex L −8, 60, −8 17.28 13
Parietal
Supramarginal L −64, −24, 30 17.22 13
The coordinates x, y, z refers to the anatomical location of the Montreal
Neurological Institute space for the clusters local maxima. p < 0.001; *p < 0.005.
L, left; R, right; F, F-values; k, number of voxels.
FIGURE 2 | Performances on the scanner working-memory task. (A)
A significant (p = 0.01) main effect of group in performance accuracy
was shown with superior performances for patients with Parkinson’s
disease without MCI compared to patients with MCI. The
group-by-time interaction effect was not significant (p = 0.65). (B)
There was no significant group difference in reaction time (main
effect, p = 0.58), but the group-by-time interaction effect was close to
significant (p = 0.07).
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FIGURE 3 | Main effects of group across time-points, comparing
BOLD-signal intensity in patients with Parkinson’s disease with or
without MCI. (A) The presented results are chosen to illustrate
fronto-striatal respective posterior cortical circuitry (with two opposite
patterns). significant main effect of group (red) was shown in bilateral
medial PFC/ACC (A), left superior parietal/occipital cortex (B), and putamen
(C), where patients with MCI (n = 11) showed reduced BOLD-signal
intensity compared to patients without MCI (n = 28). An opposite pattern
was shown in left supramarginal gyrus (D) were patients with MCI showed
larger BOLD-signal intensity compared to patients without MCI. Mean beta
values are presented as plots contrasting working-memory 2-back task with
the baseline resting condition for patients with Parkinson’s disease without
MCI (green), and patients with MCI (blue). Error bars are 1 SE. Z,
anatomical location in Montreal Neurological Institute transversal space.
The statistical threshold in the pictures (red clusters) is set to p < 0.005 to
increase visibility.
PDMCI+ between right fusiform gyrus and bilateral caudate
nucleus (15 voxels located in MNI-space x = −16, y = 18, z =
4, and 13 voxels in x = 18, y = 10, z = 14), and as a trend in
right pre-central gyrus (32 voxels in x = 56, y = 8, z = 40), Less
conclusive evidence due to potential influences of the scanner fac-
tor, was observed in left pre-central gyrus, and in left superior
intraparietal sulcus (Supplementary Note 2). The functional con-
nectivity between right fusiform gyrus and other brain regions
did not decline as function of time.
ROI analysis
In a previous study (Ekman et al., 2012), we reported that
PDMCI+ under-recruited parts of the ACC and also the right
caudate already at the time for initial PD-diagnosis compared
to PDMCI−. In keeping with those findings, the group differ-
ences remained in parts of the ACC and contiguous areas as
shown in the whole-brain analyses of our current study. However,
the whole-brain analysis did not reveal any group difference in
the caudate, and we therefore applied the right caudate ROI
from our previous cross-sectional study (Ekman et al., 2012).
The group difference in the right caudate ROI was weakened at
follow-up and themain effect of group was now only approaching
significance (p = 0.07).
DISCUSSION
In a population-based cohort of newly diagnosed patients with
incident PD, we showed that PDMCI+ performed inferior across
time-points on the fMRI working-memory task compared to
PDMCI−. Evaluations of longitudinal changes in functional
brain responses showed a group-by-time interaction effect in the
right fusiform gyrus, where PDMCI+ longitudinally decreased
their BOLD-signal intensity whereas PDMCI− were stable across
time-points. In addition to the longitudinal change, compared
to PDMCI−, PDMCI+ displayed under-recruited BOLD-signal
intensity across time in medial prefrontal cortex.
The fusiform gyrus is primarily associated with higher-order
visual processing, but also with visual working-memory pro-
cessing (Cuortney et al., 1997; Wager and Smith, 2003; Chang
et al., 2007; Rottschy et al., 2012). It has been hypothesized
that working-memory maintenance may involve the same cor-
tical regions that initially process the representations to be held
in working-memory (D’Esposito, 2007). We confirmed with the
PPI analysis that the right fusiform gyrus is functionally con-
nected with bilateral caudate nucleus, bilateral pre-central gyrus
and left intraparietal sulcus during working-memory processing
(Gazzaley et al., 2004). Critically, such connectivity was more
robust for PDMCI− compared to PDMCI+. The reported alter-
ations in the right fusiform gyrus may thus reflect a longitudinal
change in PDMCI+ that is related to working-memory mainte-
nance. However, the right fusiform gyrus change might precede
additional cognitive decline for PDMCI+ at follow-up (Bateman
et al., 2012). Structural changes in the fusiform gyrus have been
reported for patients with PD and MCI compared to patients
without MCI (Pagonabarraga et al., 2013), as well as marked
reductions in gray matter density in patients with PDD (Nagano-
Saito et al., 2005; Ramírez-Ruiz et al., 2005). Functional changes
have been related to evolving glucose metabolism decline within
cognitive networks with both posterior and prefrontal cortical
basis in patients with PD (Huang et al., 2007), but impairments
in cognitive measures mediated by pathology in posterior corti-
cal regions rather than fronto-striatal regions have been proposed
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FIGURE 4 | Group-by-time interaction effect, comparing BOLD-signal
intensity in patients with Parkinson’s disease with or without MCI. (A) A
significant group-by-time interaction effect (red) was shown in the right
fusiform gyrus comparing patients with Parkinson’s disease and MCI (n = 11)
to patients without MCI (n = 28). The task-specific activation for all included
participants with Parkinson’s disease are presented as a yellow outline to
illustrate the contrast between 2-back working-memory processing and
resting baseline-condition (p < 0.05, family-wise error corrected). (B) Mean
beta values are presented as plots for patients with Parkinson’s disease
without MCI (green), and with MCI (blue) at both time-points. (C) All patients
with Parkinson’s disease and MCI showed a negative slope across time with
decreased BOLD-signal intensity (each participants is represented as a line in
the figure). Error bars are 1 SE. Z, anatomical location in Montreal
Neurological Institute transversal space.
Table 3 | Group-by-time interaction effects in BOLD-signal intensity
between patients with Parkinson’s disease with and without MCI.
Brain regions Side Peak (x, y, z) F K
PATIENTS WITH MCI SHOW DECREASED BOLD-SIGNAL INTENSITY
LONGITUDINALLY
Fusiform gyrus R 38, −48, −22 26.45 86
Vermis R 4, −52, −20 19.87 19
Inferior temporal* L −48, −2, −38 13.25 23
PATIENTS WITH MCI SHOW INCREASED BOLD-SIGNAL INTENSITY
LONGITUDINALLY
Dorsolateral prefrontal* L −42, 44, 26 14.43 45
Superior parietal* R 22, −52, 60 13.36 26
The coordinates x, y, z refers to the anatomical location of the Montreal
Neurological Institute space for the clusters local maxima. p < 0.001; *p < 0.005.
L, left; R, right; F, F-values; k, number of voxels.
to predict prodromal PDD (Williams-Gray et al., 2007, 2013).
Correspondences of brain atrophy in temporal-parietal regions
between patients with PD and Alzheimer’s disease have also been
reported to predict long-term cognitive decline (Weintraub et al.,
2012).
In a previous cross-sectional study, we reported that newly
diagnoses drug-naïve patients with PDMCI+ under-recruited
bilateral ACC and right caudate during working-memory updat-
ing (Ekman et al., 2012). In agreement with that, we show
in the present study that PDMCI+ under-recruited bilateral
medial prefrontal cortex (including ACC) compared to PDMCI−,
and that the alterations persist across time. ACC is related to
high-level cognitive processing (Duncan and Owen, 2000), and
PD-related alterations are associated with striatal dopaminergic
depletions (Ito et al., 2002), decreased metabolism (Polito
et al., 2012), and loss of neuronal integrity (Lewis et al.,
2012).
In agreement with our previous cross-sectional study, persis-
tent striatal alterations were shown in the present study, where
PDMCI+ showed inferior BOLD-signal intensity in right puta-
men and in the right caudate ROI compared to PDMCI−.
However, a main effect of scanner overlapped with the main effect
of group in the right putamen, which make this evidence less
conclusive, even though large scanner-specific effect sizes were
evident. Striatal alterations are repeatedly reported in the early
phase of PD in relation to cognitive impairment and depleted
dopaminergic circuitry (Sawamoto et al., 2008; Kehagia et al.,
2010; Ekman et al., 2012), and dopamine synthesis capacity in the
putamen and caudate positively correlates with working-memory
capacity (Cools et al., 2008). A weakened group difference was
revealed in the right caudate ROI when comparing PDMCI+ to
PDMCI− longitudinally, potentially reflecting a beneficial med-
ication effect due to onset of anti-parkinsonian treatment. A
positive treatment effect might also partly explain the lack of
further behavioral decline for PDMCI+ on the scanner working-
memory task, and on the cognitive tests outside the scanner.
However, anti-parkinsonian dopaminergic medication has pre-
viously shown both positive and negative outcomes on cognitive
functions (Cools, 2006), and given the relatively small sample size,
potential cognitive effects of dopaminergic medication on brain
activation is speculative.
The reported alterations might be associated to addi-
tional neurochemical dysfunction. Hypo-metabolism have been
reported in patients with PD and multi-domain MCI com-
pared to patients with normal cognition in lateral frontal cortex,
ACC, and parietal-temporal-occipital cortices (Lyoo et al., 2010).
Patients with PD commonly demonstrate cortical cholinergic
dysfunction that is more pronounced in PDD (Bohnen et al.,
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2003), and covariance between striatal 18F-fluorodopa (FDOPA)
reduction and decreased cortical cholinergic binding in frontal
and temporal-parietal cortices have been reported in PDD (Hilker
et al., 2005). Furthermore, degeneration of locus coeruleus (LC)
might affect executive processes due to deficits in norepinephrine
(NE) transmission (Marsh et al., 2009; Vazey and Aston-Jones,
2012). The LC region mainly projects to parietal, temporal, and
frontal regions. Thus, the current findings suggest an early evolv-
ing pattern in PDMCI+ consisting of posterior cortical change
that might relate to evolving norepinephrine and/or cholinergic
dysfunction.
In contrast to inferior BOLD-signal intensity for PDMCI+,
we report group-by-time interaction effects in right parietal
cortex indicating up-regulated BOLD-signal intensity between
baseline and follow-up for PDMCI+, whereas PDMCI− were
stable across time. Additionally, PDMCI+ recruited parts of
the left supramarginal gyrus to a larger extent than PDMCI−
across time. The supramarginal gyrus has been proposed as
part of the phonological loop and is associated to working-
memory span and interference control (Burgess et al., 2011). The
reported up-regulations could potentially reflect increased effort
in performing the fMRI working-memory task due to evolv-
ing cognitive impairments related to fronto-striatal and temporal
circuitry. The increased activation might also relate to compen-
satory regulations for the observed fronto-striatal alterations, and
might in part explain the lack of additional behavioral decline at
follow-up.
The longitudinal method is a strength as it increases the ability
to generalize the reported effects (Raz, 2005; Nyberg et al., 2010),
whereas the repeated neuropsychological assessments increases
the prognostic accuracy of MCI with respect to prodromal PDD
(Pedersen et al., 2013). Data acquisition was conducted on two
different scanners and is a limitation that might have induced
additional variability. The detection ability is also more restricted
in subcortical regions for the 1.5T scanner compared to the
3T scanner (Nyberg et al., 2007). More importantly, the scan-
ner confound risk making interpretations of group differences
unreliable. Critically, the reported differences showed medium to
large effect sizes on scanner-separated sub-analyses. Nevertheless,
regions showing overlap between group differences and effects of
scanner should be interpreted with caution. The relatively small
PDMCI+ sample is a limitation, and affected the ability to gen-
eralize the findings to the general PD-population. Furthermore,
our criteria for assessing MCI was not completely fulfilled (i.e.,
not two measures in each domain) which might have affected
detection ability and also prevented sub-analyses of domain-
specific MCI.
In conclusion, we report longitudinal BOLD-signal reduc-
tions in the right fusiform gyrus for PDMCI+ compared to
PDMCI−. In addition, compared to PDMCI−, PDMCI+ showed
persistent but non-changing under-recruitment across time in
fronto-striatal circuitry in relation to deficits in working-memory
updating. Taken together, the results are in keeping with the
notion that the longitudinal development of cognitive impair-
ment in PD reflect posterior cortical change rather than fur-
ther fronto-striatal changes. Our population-based longitudinal
approach thus adds further knowledge of how task-evoked brain
responses relate to cognitive impairments in PD.
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